CABA

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cabaletta Bio (CABA – Research Report) and Bausch + Lomb Corporation (BLCO – Research Report). Cabaletta Bio (CABA) In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Cabaletta Bio, with a price target of $13.00. The company's shares closed last Tuesday at $0.73, close to its 52-week low of $0.59. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cabaletta-bio-caba-and-bausch-lomb-corporation-blco?utm_source=advfn.com&utm_medium=referral